SCHEMBL4079431

SCHEMBL4079431

O=C(N[C@H]1CNC1=O)OCc1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
NAAA Q02083 16/20 0.85
CTSL P07711 1/20 0.70
ASAH1 Q13510 3/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4073930 1.00 NAAA (0.85) NAAACTSLASAH1
SCHEMBL4073924 1.00 NAAA (0.85) NAAACTSLASAH1
SCHEMBL17556838 0.95 NAAA (0.81) NAAACTSLASAH1
SCHEMBL16058437 0.92 NAAA (1.00) NAAACTSLASAH1
SCHEMBL19646601 0.92 NAAA (1.00) NAAACTSLASAH1
SCHEMBL19646593 0.92 NAAA (1.00) NAAACTSLASAH1
SCHEMBL17556784 0.90 NAAA (0.78) NAAACTSLASAH1
SCHEMBL17557032 0.89 NAAA (0.80) NAAACTSLASAH1
SCHEMBL17556798 0.89 NAAA (0.69) NAAACTSLASAH1
SCHEMBL17577509 0.89 NAAA (0.80) NAAACTSLASAH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10363237-B2 Compositions and methods of inhibiting N-acylethanolamine-hydrolyzing acid amidase THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2019-07-30 US disclosed
US-9908848-B2 Amide derivatives of lactam based N-acylethanolamine acid amidase (NAAA) inhibitors THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-03-06 US disclosed
US-9828338-B2 Carbamate derivatives of lactam based N-acylethanolamine acid amidase (NAAA) inhibitors THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-11-28 US disclosed
US-20160256432-A1 COMPOSITIONS AND METHODS OF INHIBITING N-ACYLETHANOLAMINE-HYDROLYZING ACID AMIDASE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2016-09-08 US disclosed
US-20160068482-A1 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2016-03-10 US disclosed
US-20160068483-A1 AMIDE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2016-03-10 US disclosed
US-8324198-B1 Monocarbams PFIZER INC. (US) 2012-12-04 US disclosed
US-20120289455-A1 Monocarbams PFIZER INC. 2012-11-15 US disclosed
US-8252782-B2 Monocarbams PFIZER INC. (US) 2012-08-28 US disclosed
US-8252782-B2 Monocarbams PFIZER INC. (US) 2012-08-28 US disclosed
US-4670553-A 2-oxo-1-(aminocarbonylaminosulfonyl-aminocarbonyl)azetidines E. R. SQUIBB & SONS, INC. (US) 1987-06-02 US disclosed
CN-86106980-A The alkylsulfonyl that 2-oxo-1-{[(replaces)-and amino] carbonyl } azetidine-typed 1987-04-08 CN disclosed
US-4584132-A UROGENITAL AND RESPIRATORY DISORDERS;AZETIDINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 1986-04-22 US disclosed
US-4576749-A 3-Acylamino-1-carboxymethylaminocarbonyl-2-azetidinones E. R. SQUIBB & SONS, INC. (US) 1986-03-18 US disclosed
US-4551277-A 4-(3-Acylamino-2-oxo-1-azetidinyl)-4-oxo-2-butenoic acid E. R. SQUIBB & SONS, INC. (US) 1985-11-05 US disclosed
EP-0061765-B1 BETA-LACTAMS E.R. SQUIBB & SONS, INC. (US) 1985-08-28 EP disclosed
EP-0138407-A1 Azetidinones E.R. Squibb & Sons, Inc. (US) 1985-04-24 EP disclosed
US-4478749-A AMINO ACID DERTIVATIVES ANTIBIOTICS E. R. SQUIBB & SONS, INC. (US) 1984-10-23 US disclosed
EP-0085291-A1 2-Oxo-1-(aminocarbonylaminosulfonylaminocarbonyl)azetidines E.R. Squibb & Sons, Inc. (US) 1983-08-10 EP disclosed
EP-0061765-A1 Beta-Lactams E.R. SQUIBB & SONS, INC. (US) 1982-10-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289455-A1 Monocarbams MRPL21, C1R, C5AR1 NAAA 3008/4885CTSL 1452/4885ASAH1 3788/4885
US-20160068482-A1 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS NAAA, FAAH, FAAH2 NAAA 1/4885CTSL 945/4885ASAH1 106/4885
US-10363237-B2 Compositions and methods of inhibiting N-acylethanolamine-hydrolyzing acid amidase NAAA, NAPEPLD, FAAH NAAA 1/4885CTSL 849/4885ASAH1 64/4885
US-20160256432-A1 COMPOSITIONS AND METHODS OF INHIBITING N-ACYLETHANOLAMINE-HYDROLYZING ACID AMIDASE NAAA, NAPEPLD, FAAH NAAA 1/4885CTSL 849/4885ASAH1 64/4885
US-20160068483-A1 AMIDE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS NAAA, FAAH, FAAH2 NAAA 1/4885CTSL 1484/4885ASAH1 88/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.